CMS has released their latest round of drug pricing data – this one reflecting price changes from arguably the peak of COVID-19 hysteria and supply chain pressure. The release gives us long-anticipated insight into how the drug supply chain is operating as it is pushed up against the wall by unprecedented disruption. Surveys have shown that Americans believe that the pandemic will yield drug price increases from manufacturers, and given the growing number of shortages, who can blame them? Well, the CMS data shows that everyone may be in for a surprise: overall, generic drug prices don’t appear to be budging.
Read More
For the past 20 months, in the pre-COVID-19 era, we’ve released a monthly report called “What’s Happening To Generic Drug Prices,” where we track month-by-month price changes from the CMS National Average Drug Acquisition Cost (NADAC) survey of community pharmacy invoice acquisition costs for prescription drugs. This month, we still are providing that update, but in digging through the latest round of drug pricing data from CMS, we spotted some very interesting drug pricing movement on generic drugs, and one massive increase on a drug that was recently being tested for emergency use for treatment of COVID-19 patients. Check out our latest drug pricing report for important updates on the latest drug price changes, plus an updated NADAC Packed Bubble Chart and Abnormal Drug Price Increase Tracker.
Read More
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw more price increases this past month, but an overall decrease in annualized spending based on typical utilization trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart. Happy New Year.
Read More
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw less price increases this past month, and an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart.
Read More
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, but an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. For those that have followed previous 46brooklyn reports, there are several familiar drugs that experienced significant pricing movement this past month, so this piece will be a good trip down memory lane. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.
Read More
Last week, we were met with a delightful surprise as we were perusing through the CMS website and discovered an out-of-the-blue drug pricing data update just begging to be downloaded. The hidden treasure was the freshly-updated CMS State Utilization database, which provides quarterly drug pricing data that shows what state Medicaid programs are spending on prescription drugs, providing an excellent window into the price-setting practices of the prescription drug supply chain. This most recent CMS data update ended up filling in most of the Q3 2018 divots and extended the 2018 data to include large portions of the fourth quarter. We have updated all of our dashboards that rely on this dataset, rolling all of them forward to Q4 2018. We couldn't resist sneaking an extended peak at the data, and while we will offer more in-depth analyses soon, we wanted to give some of our initial takeaways.
Read More